We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Coconut Oil and Rapeseed Oil Treated Differently by the Liver
News

Coconut Oil and Rapeseed Oil Treated Differently by the Liver

Coconut Oil and Rapeseed Oil Treated Differently by the Liver
News

Coconut Oil and Rapeseed Oil Treated Differently by the Liver

Fat droplets in a cell. Credit: (c) Johanna Spandl / Universität Bonn.
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Coconut Oil and Rapeseed Oil Treated Differently by the Liver"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Coconut oil has found its way into German kitchens more and more often in recent years, although its alleged health-promoting effect is controversial. Scientists from the University of Bonn have now been able to show how it is metabolized in the liver. Your results could also have consequences for the treatment of certain diarrheal diseases. The results have appeared in the journal Molecular Metabolism.

Coconut oil differs from rapeseed or olive oil in the fatty acids it contains. Fatty acids consist of carbon atoms bonded to one another, usually 18 in number. In coconut oil, however, most of these chains are significantly shorter and contain only 8 to 12 carbon atoms. In the liver, these medium-chain fatty acids are partially converted into storage fats (triglycerides). How exactly this happens was previously largely unknown.


The new study now sheds light on this: "There are two enzymes in the liver for storage fat synthesis, DGAT1 and DGAT2," explains Dr. Klaus Wunderling from the LIMES Institute (the acronym stands for "Life & Medical Sciences") at the University of Bonn. "We have now seen in the liver cells of mice that DGAT1 primarily processes medium-chain fatty acids and DGAT2 long-chain ones."


In their experiments, the scientists blocked DGAT1 with a special inhibitor. The synthesis of storage fats from medium-chain fatty acids decreased by 70 percent as a result. The blockade of DGAT2, however, led to a reduced processing of long-chain fatty acids. "The enzymes seem to prefer different chain lengths," concludes Prof. Dr. Christoph Thiele from the LIMES Institute, who led the study and is also a member of the Immunosensation Cluster of Excellence.


Surprising side effect


Whether fatty acids are actually used in the liver to build up storage fat depends on the current energy requirement. When the body needs a lot of energy, the so-called beta-oxidation is started - the fatty acids are in a sense "burned" directly. This metabolic pathway is of great medical interest. In the case of diabetes, for example, it might be useful to reduce beta-oxidation. Because then the body has to meet its energy needs from glucose instead - the blood sugar level drops, with positive consequences for the disease.


Therefore, around 40 years ago, pharmaceutical researchers developed a corresponding inhibitor, Etomoxir. It binds to enzymes for beta oxidation and brings them to a standstill. However, it quickly became apparent that Etomoxir had massive side effects.


The Bonn researchers have now discovered a possible reason for this: with Etomoxir, they inhibited the combustion of medium-chain fatty acids in mice, in the expectation that it would stimulate the production of storage fat. “Instead, fat synthesis also decreased significantly, but only from storage fats with medium-chain fatty acids,” explains Wunderling. “We therefore suspect that Etomoxir also switches off the DGAT1 enzyme.” In the development of new inhibitors for beta oxidation, one must pay attention to such effects in the future.


Another interesting finding is that Austrian and Dutch scientists published a few years ago: They examined patients who suffer from chronic diarrheal diseases. In 20 of them, they found changes in the DGAT1 gene, which became functionless as a result. "We now want to find out whether the impaired processing of medium-chain fatty acids is responsible for the digestive problems," says Wunderling. The DGAT1 enzyme is not only active in the liver, but also in the intestine. Perhaps his disorder therefore causes diarrhea when those affected ingest medium-chain fatty acids. Wunderling: "In this case you could possibly simply help them - through an appropriate diet."

Reference
Wunderling K, Leopold C, Jamitzky I, et al. Hepatic synthesis of triacylglycerols containing medium-chain fatty acids is dominated by diacylglycerol acyltransferase 1 and efficiently inhibited by etomoxir. Molecular Metabolism. 2021;45:101150. doi:10.1016/j.molmet.2020.101150



This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement